2025年1月3日 · Guidelines recommend that most patients hospitalized for acute PE who are treated with parenteral anticoagulation should receive low-molecular-weight heparin (LMWH) rather than unfractionated heparin (UFH) because LMWH achieves therapeutic anticoagulation more quickly and is associated with fewer bleeding complications. 1-3

2020年10月2日 · For patients with PE with echocardiography and/or biomarkers compatible with right ventricular dysfunction but without hemodynamic compromise (submassive PE), the ASH guideline panel suggests anticoagulation alone over the routine use of thrombolysis in addition to anticoagulation (conditional recommendation based on low certainty in the ...

2020年1月27日 · Anticoagulation should be initiated as soon as the diagnosis of PE is suspected. 8 Unfractionated heparin may be preferred in patients who are candidates for further advanced therapies such as thrombolysis, catheter-directed thrombolytics or embolectomy, or surgical embolectomy because it provides more flexibility for procedures. 4 Direct oral ...

2025年2月27日 · The treatment, prognosis, and follow-up of patients with acute PE are reviewed here. The epidemiology, pathophysiology, clinical presentation, and diagnosis of PE, as well as detailed discussions of anticoagulation and thrombolysis in patients with PE are presented separately. (See "Pulmonary embolism: Epidemiology and pathogenesis in adults".)

Patients with PE should remain on anticoagulation for a treatment phase of 3 months as primary therapy. 5 This recommendation includes patients with a transient provoking risk factor such as surgery with general anesthesia, confinement to bed for at least 3 days with an acute illness, Cesarean section, estrogen therapy, pregnancy or puerperium ...

2025年2月27日 · Reversal of anticoagulation in intracranial hemorrhage; Society guideline links: Superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism ... Thrombolytic therapy is used in patients with acute pulmonary embolism (PE) to rapidly dissolve thrombus and improve cardiorespiratory hemodynamics. While anticoagulant therapy is ...

2024年10月7日 · ESC/ERS recommend initial anticoagulation with unfractionated heparin (UFH) in patients with suspected high-risk PE. ESC/ERS, PERT, and NICE recommend UFH for hemodynamically unstable PE if advanced therapies (e.g., thrombus extraction, fibrinolysis, or surgery) are being considered.

Current anticoagulation management guidelines prefer direct oral anticoagulants (DOAC) for initial and long-term therapy for treating PE [4]. Dabigatran, rivaroxaban, apixaban, and edoxaban are preferred over vitamin K antagonist (VKA) therapy.

Trends in discharge rates for acute pulmonary embolism in U.S. emergency departments. Ann Intern Med. 2024;177 (2):134-143. doi: PubMed Google Scholar Crossref.

Long-term anticoagulation is essential for patients who survive an initial DVT or pulmonary embolism. The optimum total duration of anticoagulation is controversial, but general consensus...

2023年9月7日 · Anticoagulants are the cornerstone of therapy for PE and DVT. The direct oral anticoagulants (DOACs), which are both more convenient and safer than conventional therapies when used appropriately, have dramatically changed the VTE treatment landscape over the last...

Untreated acute pulmonary embolism (PE) is associated with a mortality rate of up to 25% 1, and anticoagulation has been the backbone of PE treatment for decades. The goal of treatment is to reduce mortality by prevention of thrombus extension, embolization and/or formation of …

2025年2月27日 · Venous thromboembolism, comprising pulmonary embolism and deep vein thrombosis, is a common disease with considerable mortality and morbidity, such as post-thrombotic and post-pulmonary-embolism syndrome.1,2 Anticoagulation is the main treatment for venous thromboembolism, although the decision on how, and for how long, anticoagulant treatment should be administered is increasingly complex.

2021年7月1日 · Pulmonary embolism (PE) is the most severe clinical presentation of venous thromboembolic disease (VTE). 1 Anticoagulant treatment is the cornerstone of its management, because it reduces the risk of VTE recurrence (including fatal PE recurrence) but at the cost of an increased risk of bleeding.

Warfarin is also licensed for the treatment and prophylaxis of DVT and PE. Apixaban should be taken orally. The recommended dose of apixaban for the treatment of pulmonary embolism is 10 mg twice daily for 7 days, followed by a maintenance dose …

2017年3月1日 · Anticoagulation is the mainstay of VTE treatment. Most patients with deep venous thrombosis or low-risk pulmonary embolism can be treated in the outpatient setting with low-molecular-weight...

4 天之前 · For patients at high risk for recurrent venous thromboembolism (VTE), the American College of Chest Physicians (ACCP) recommends extended treatment with reduced-dose anticoagulation (NEJM JW Gen Med Nov 1 2021 and Chest 2021; 160:545).Although the recommendation is based on two randomized trials (NEJM JW Gen Med Jan 15 2013 and N Engl J Med 2013; 368:699; NEJM JW Gen Med Apr 15 2017 and N Engl ...

2025年2月1日 · Pulmonary embolism (PE) mortality has increased over the past decade and racial and geographic disparities persist. Black women and men have an approximately two-fold higher age-adjusted mortality rate compared with White women and men, respectively. Similar trends are seen in geographical regions.

Primary systemic fibrinolysis has an unfavorable risk–benefit ratio in intermediate-risk PE; catheter-directed techniques are an option for patients with hemodynamic decompensation and high bleeding risk. New oral anticoagulant agents are effective and safe alternatives to standard anticoagulation regimens.

Anticoagulation is the main treatment approach in venous thromboembolism treatment. Current guidelines recommend a two phase anticoagulation treatment: NICE suggest (4): Anticoagulation treatment for proximal DVT or PE. measure baseline full blood count, renal and hepatic function, PT and APTT but start anticoagulation before results available.